October 2, 2017 09:16 AM EDT

Rigel surges as FDA waives panel; Troubled Endocyte looks for comeback following $12M licensing deal; Seattle Genetics scores a ‘breakthrough’

→ Shares of Rigel Therapeutics $RIGL bounded up about 20% this morning after the biotech reported that the FDA has no plans to call …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Rigel surges as FDA waives pan­el; Trou­bled En­do­cyte looks for come­back fol­low­ing $12M li­cens­ing deal; Seat­tle Ge­net­ics scores a ‘break­through’